Efficacy of erenumab 70 mg in chronic migraine: Vicenza experience

Neurol Sci. 2020 Dec;41(Suppl 2):479-480. doi: 10.1007/s10072-020-04665-2.

Authors

Caterina Disco¹, Giuseppe Billo², Antonella De Boni², Cristina De Luca², Francesco Perini²

Affiliations

¹ Headache Center - Neurology Department, San Bortolo Hospital, Viale Rodolfi n 37, 36100, Vicenza, Italy. caterina.disco@aulss8.veneto.it.
² Headache Center - Neurology Department, San Bortolo Hospital, Viale Rodolfi n 37, 36100, Vicenza, Italy.

PMID: 32845488
DOI: 10.1007/s10072-020-04665-2

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Calcitonin Gene-Related Peptide Receptor Antagonists
Humans
Migraine Disorders* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
erenumab